Drug Pricing Investigation: Teva--Copaxone
Loading...
Serial Number
Levin Center Identifier
Document Date
2020-09-30
Report Length
55 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Report Type
Found Using Methodology
Yes
Committee(s)
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
Teva raised Copaxone's price 27 times since its launch in 1997, resulting in a yearly course costing nearly $70,000, compared to less than $10,000 in 1997. Teva's price increases contributed to over $34 billion in Copaxone net U.S. revenue, accompanied by millions in executive compensation. The report concludes that structural reforms, such as Medicare negotiation, are essential to address the pharmaceutical industry's pricing practices.